Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Hematologic Neoplasms × olaparib × Clear all

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Ovarian Neoplasms 15 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Breast Neoplasms 4 Fallopian Tube Neoplasms 3 Neoplasm Metastasis 2 Metastatic Castration-resistant Prostate Cancer 2 Endometrial Neoplasms 2 Carcinoma 2 Small Cell Lung Carcinoma 1 Sarcoma 1 Prostatic Neoplasms 1 Peritoneal Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Neoplasms 1 Hematologic Neoplasms 1 HER2-ve Metastatic Breast Cancer 1 Colorectal Neoplasms 1 Carcinoma, Ovarian Epithelial 1

Interventions

Olanzapine 4 Cyclophosphamide 4 Voriconazole 3 Tranexamic Acid 3 Standard of Care 3 Zoledronic Acid 2 Practice Guidelines as Topic 2 Methods 2 Educational Status 2 Early Intervention, Educational 2 Doxorubicin 2 trihexyltetradecylphosphonium chloride 1 thymoglobulin 1 shengxuening 1 pembrolizumab 1 olaparib 1 letermovir 1 lenvatinib 1 fludarabine phosphate 1 ferrous succinate 1 fedratinib 1 cilgavimab and tixagevimab drug combination 1 apixaban 1 Whole-Body Irradiation 1 Vincristine 1 Thalidomide 1 Tazobactam 1 Specimen Handling 1 Sirolimus 1 Piperacillin, Tazobactam Drug Combination 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03486873 2026-03-16

MK-3475-587

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡